Open AccessSingle-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection
Author(s) -
Kun Li,
Zhuo Li,
Christine L. WohlfordLenane,
David K. Meyerholz,
Rudragouda Channappanavar,
Dong Sung An,
Stanley Perlman,
Paul B. McCray,
Biao He
Publication year - 2020
Publication title -
mbio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.562
H-Index - 121
eISSN - 2161-2129
pISSN - 2150-7511
DOI - 10.1128/mbio.00554-20
Subject(s) - virology , middle east respiratory syndrome coronavirus , immunization , nasal administration , coronavirus , medicine , covid-19 , recombinant dna , biology , immunology , antibody , infectious disease (medical specialty) , disease , pathology , biochemistry , gene
MERS-CoV causes lethal infection in humans, and there is no vaccine. Our work demonstrates that PIV5 is a promising vector for developing a MERS vaccine. Furthermore, success of PIV5-based MERS vaccine can be employed to develop a vaccine for emerging CoVs such as SARS-CoV-2, which causes COVID-19.